CMS Says It Blocked $1.6 Billion in Medicare Lab Payments: What Genetic Testing Labs Should Do Now
Short answer: CMS says it has blocked more than $1.6 billion in potentially fraudulent Medicare laboratory payments since the current administration began, including $732 million tied to 157 revoked providers and suspensions affecting 600 labs. CMS credits AI and machine-learning analytics. Genetic testing labs should expect payment-suspension scrutiny and prepare documentation before a notice arrives.
What CMS reported
According to Fierce Healthcare's report on the CMS announcement, CMS has blocked over $1.6 billion in potentially fraudulent Medicare lab payments since the second Trump administration began, with figures current as of August 28, 2026. The agency's breakdown: $732 million tied to 157 providers revoked from Medicare, more than $500 million in suspected fraudulent payments from 185 suspensions affecting 600 labs, $276 million from 442 identified overpayments, and $127 million from law enforcement referrals.
CMS Administrator Mehmet Oz said that "when laboratories bill Medicare for tests they never performed, it drains the Medicare Trust Fund," and described building "a technology-powered fraud prevention operation," per the same report. These are CMS's own figures. A payment suspension is not a finding of fraud, and the totals mix suspended, recovered, and referred amounts, so they should not be read as proven losses.
How CMS says it finds these labs
CMS told Fierce Healthcare it uses "advanced analytics usage, including artificial intelligence and machine-learning models" to spot billing patterns. The reported focus is labs billing for medically unnecessary services to patients who lack an established relationship with the ordering provider. CMS's Fraud Defense Operations Center, per the same report, accounted for more than $371 million in suspended payments involving 267 providers and suppliers since January 1, 2026.
CMS's own fraud page states that total Medicare program integrity savings rose 59%, from $26.3 billion in FY 2024 to $41.9 billion in FY 2025, a return of $22.3 for every $1 spent. The same page names fraudulent genetic testing, enrollment violations, and hospice fraud as fraud spotlights. For a lab, that means a data-driven screen is running against your claims whether or not you have ever been audited.
Why genetic testing sits in the crosshairs
MedTech Dive reported that of the $8.4 billion Medicare spent on lab tests in 2024, genetic tests accounted for 43% of spending but only 5% of tests, up from an 18% spending share in 2018. HHS-OIG's February 2026 analysis, covered by Healthcare Dive, put 2024 genetic test spending at $3.6 billion, a 20% year-over-year increase. MedTech Dive also recounts a 2019 federal case charging 35 people over $2.1 billion in alleged fraudulent genetic testing billing. Separately, the National Law Review reported that DOJ's 2026 National Health Care Fraud Takedown involved 455 defendants and $6.5 billion in alleged fraud.
The pattern CMS describes, high dollars per test and tests ordered without a real clinician-patient relationship, is the pattern analytics tools are built to flag. Legitimate labs can look statistically similar to bad actors if their documentation is thin, which is why the controls below matter. This follows the February 2026 request for information we covered in our CMS CRUSH rule explainer, which asked whether MolDX registration should be broadened nationally.
What genetic testing labs and RCM teams should do now
Start with ordering-provider validation. Confirm every ordering clinician has an active NPI and a documented treating relationship with the patient, and treat orders from telehealth-only or marketing-sourced channels as high risk. Second, verify medical necessity before the specimen is run: our guide to Medicare coverage for genetic testing explains how NCDs, LCDs, and MolDX policies define it, and our denial-prevention guide covers the documentation packet.
Third, keep enrollment data current. Stale ownership or address information on file with your Medicare contractor is an avoidable risk. Fourth, make sure each molecular test you bill carries the correct registered identifier, as described in our DEX Z-code guide. Fifth, monitor your own data the way an analytics model would: track claims per ordering provider, test volume spikes, and denial rates, and investigate outliers before a contractor does. Finally, write a suspension-response plan now. Name who receives notices, who engages counsel, and how you will assemble records quickly, since the response window after a notice is short. Teams comparing intake and documentation workflows can see the approach on the ScreenMyGene homepage.
What to watch next
Three developments are worth tracking. The first is the CRUSH proposed rule, which CMS has targeted for October 2026 and which could widen suspension and revocation triggers. The second is whether CMS publishes updated revoked-provider lists and quarterly progress reports, which its fraud page says it maintains. The third is how contractors apply analytics-based flags in practice, because the line between an audit request and a payment suspension determines how much cash a lab can lose while it proves its case. Labs that are already building clean order-to-claim documentation will be best positioned under any of these outcomes.
FAQ
How much has CMS said it blocked in lab payments?
CMS says it has blocked more than $1.6 billion in potentially fraudulent Medicare lab payments since the current administration began, as of August 28, 2026. That includes $732 million tied to 157 revoked providers and more than $500 million from 185 suspensions. These are CMS figures and are not final adjudications of fraud.
How does CMS identify suspect labs?
CMS says it uses advanced analytics, including artificial intelligence and machine-learning models, to detect suspicious billing patterns. The reported focus is labs billing medically unnecessary services for patients without an established relationship with the ordering provider. CMS has not published the models or thresholds, so labs should monitor their own outliers.
Does a payment suspension mean a lab committed fraud?
No. A suspension is an administrative action that withholds payment while a credible concern is investigated. It is not a finding of fraud. Labs can still face severe cash-flow strain during a suspension, so documentation of medical necessity and ordering relationships should be ready before any notice arrives.
Why are genetic tests a focus?
MedTech Dive reported genetic tests were 43% of 2024 Medicare lab spending but only 5% of tests, up from an 18% spending share in 2018. CMS's fraud page also names fraudulent genetic testing as a spotlight area. High-dollar, high-growth categories attract the most analytic scrutiny.
What is the single most useful control for labs?
Validating the ordering relationship and medical necessity before testing. Because CMS's reported focus is tests ordered for patients lacking an established relationship with the ordering provider, documentation showing a real treating relationship and a clear clinical indication is the most direct defense. Pair it with current enrollment records.
This article is provided for general educational and business-decision-support purposes for laboratory, revenue-cycle, and clinical-ordering professionals. It reports figures published by CMS and secondary sources as of October 1, 2026, and is not legal, coding, compliance, or reimbursement advice. Requirements and enforcement priorities are subject to change; consult qualified regulatory counsel and verify directly with CMS and your Medicare contractor.
Sources: Fierce Healthcare, "Trump admin blocks over $1.6B in potentially fraudulent Medicare lab payments: CMS"; CMS.gov, Crushing Fraud, Waste, and Abuse; MedTech Dive, "Genetic tests come under scrutiny in Trump administration's fraud crackdown"; Healthcare Dive, OIG genetic testing spending analysis (February 2026); National Law Review, 2026 National Health Care Fraud Takedown.